PEOPLE - Devices for Vascular Intervention (a division of Guidant) names appointment:
This article was originally published in Clinica
Michael Gropp has been named vice-preident of quality assurance and regulatory affairs at Devices for Vascular Intervention (a division of Guidant). Mr Gropp, previously director of regulatory affairs and technical services for Guidant Europe, will report to president of DVI, Bill Hawkins.
You may also be interested in...
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.